Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Jung, S. Korn, M. Hübner, C. Taube, R. Buhl (Mainz, Germany; Leiden, Netherlands). Short-term and long-term reproducibility of non-invasive clinical and inflammatory parameters in asthma. Eur Respir J 2012; 40: Suppl. 56, 304

Member's Comments

No comment yet.

Related content which might interest you: Variability and lack of predictive ability of asthma end-points in clinical trials Source: Eur Respir J 2002; 20: 1102-1109 Year: 2002 Non-invasive inflammatory markers can predict diagnosis, severity and stability of paediatric asthma Source: Eur Respir J 2006; 28: Suppl. 50, 122s Year: 2006 Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020 Comparable efficacy of calcilytic and corticosteroid in short-term and long-term allergic asthma models in vivo Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Discrepancy of non-invasive inflammatory markers and lung function tests to current level of clinical control in childhood asthma Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 The usefulness of the impulse oscillometry for predicting the treatment outcomes of bronchial thermoplasty in patients with severe asthma. Source: International Congress 2018 – Asthma analysis Year: 2018 Clustering of adherence variability metrics and clinical outcomes in asthma Source: International Congress 2018 – Clinical determinants of asthma and biomarkers Year: 2018 Measuring airway hyperresponsiveness: does it add to routine measures of clinical efficacy in guiding asthma therapy? Source: Eur Respir J 2006; 28: Suppl. 50, 319s Year: 2006 Accuracy in assessment of acute asthma needs improved to avoid potential adverse outcomes Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012 Follow-up of patients with severe asthma by noninvasive parameters of airway inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 52s Year: 2001 Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008 Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Do cardiac biomarkers predict long-term outcomes from exacerbations of COPD? Source: International Congress 2017 – Highlights on clinical problems in COPD Year: 2017 How can we improve our assessment of inflammation in clinical studies of COPD that use bronchial biopsies? Source: Eur Respir J 2006; 27: 248-249 Year: 2006 Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD Source: Eur Respir J 2013; 42: 891-892 Year: 2013 Clinical utility of measuring FeNO to assess inhaled corticosteroid response in asthma. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Cardiac biomarkers and long-term outcomes of exacerbations of COPD: a long-term follow-up of two cohorts Source: ERJ Open Res, 7 (1) 00531-2020; 10.1183/23120541.00531-2020 Year: 2021 Long-term efficacy of QMF149 in persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 The usefulness of the simultaneous measurement of IOS and FeNO in the management of asthma Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases Year: 2012